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a b s t r a c t
Mycobacterium avium subspecies paratuberculosis (MAP) causes a chronic intestinal infection of rumi-
nants and has been associated with the etiology of human Crohn’s disease. A MAP Hsp70/DDA subunit
vaccine previously showed a signiﬁcant reduction in fecal shedding of MAP in cattle, concomitant with
pronounced antibody production against MAP Hsp70, rather than T cell reactivity. Our hypothesis is thatvailable online 1 January 2011
eywords:
ycobacterium paratuberculosis
0kD heat shock protein
attle
if Hsp70-speciﬁc antibodies are able to confer protection, the ﬁrst requisite would be that the Hsp70
molecule is accessible for antibodies in intact MAP bacteria. In the current study monoclonal antibodies
identiﬁed MAP Hsp70 B cell epitopes. Two linear epitopes were also recognized by antibodies of vacci-
nated calves and goats. These epitopes showed to be accessible by antibodies in the bacterial cell wall and
in intestinal lesional tissue during natural infection. These results indicate that vaccination-induced anti-
bodies can bind intact bacteria and have the potential to contribute to the protective effect of Hsp70/DDA
st bosubunit vaccination again
. Introduction
Paratuberculosis is a highly prevalent chronic mycobacterial
nfection of the small intestine of ruminants. It causes substantial
conomic losses at farm level, particularly in cattle [1]. Transmis-
ion of the causative organism Mycobacterium avium subspecies
aratuberculosis (MAP) amongst ruminants occurs by excretion via
eces into the environment, where it may survive for prolonged
eriods of time [2]. When the disease progresses towards the clini-
al stage of infection,MAP can also be present inmilk [3]. As a result
f the latter it may represent a food safety issue given the possible
ssociation between MAP and human Crohn’s disease [4].
Currently, a vaccine to control paratuberculosis in cattle is not
vailable, since the whole cell vaccine registered for use in sheep
Abbreviations: MAP, Mycobacterium avium subspecies paratuberculosis; Hsp70,
0 kD heat shock protein.
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interferes with control programs against bovine tuberculosis. Indi-
vidual MAP proteins as subunit vaccine candidates may overcome
this interference. In bovine paratuberculosis [5,6], similar to other
mycobacterial diseases suchas tuberculosis and leprosy, heat shock
proteins (Hsp) elicit strong cell mediated and antibody responses.
Our previous studies indicated that immune responsiveness to
recombinantMAPHsp70proteins in naturally infected animalswas
predominantly cell mediated [6,7].
Since protective immunity to intracellular mycobacterial
pathogens is thought to be cell mediated [8], recombinant MAP
Hsp70 protein was used as a subunit vaccine in cattle concomi-
tant with experimental infection with MAP. It induced protection
as indicated by signiﬁcantly reduced bacterial shedding [9]. In
addition, MAP Hsp70 subunit vaccination did not interfere with
current diagnostic methods to diagnose bovine TB [10]. Surpris-
ingly, and in strong contrast with our previous observations in
ﬁeld casesofbovineparatuberculosis, this immunization-challenge
study showed limited cell mediated responses against MAP Hsp70
and pronounced MAP Hsp70 speciﬁc antibody production in the
vaccinated animals [9].
Open access under the Elsevier OA license.The contribution of antibodies to protection against mycobac-
terial infections is disputed by some (reviewed in [11,12]), and
supported by others (reviewed in [13]). Most of the recent studies
on serum therapy of M. tuberculosis (MTb) infection report pro-
tective effects of antibodies speciﬁc for polysaccharide bacterial
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ell wall antigens such as the polysaccharide lipoarabinomannan
reviewed in [14]). In mice, a monoclonal antibody (Ig A) directed
gainst a small surface-expressed mycobacterial heat shock pro-
ein (the 16kD -crystallin homologue) protected against early
nfection of murine lungs with MTb [15].
We hypothesize that if Hsp70-speciﬁc antibodies are able to
onfer protection, observed in cattle vaccinated with the recombi-
ant MAP Hsp70 subunit vaccine, the ﬁrst requisite would be that
he Hsp70 molecule is accessible for antibodies in intact MAP bac-
eria. We generated mouse monoclonal antibodies to determine
cell epitopes of the recombinant Hsp70 protein and focused on
inear epitopes. Subsequently, epitope-speciﬁc antibody responses,
nduced by vaccination of cattle and goats with recombinant MAP
sp70, were analyzed to assess whether these antibodies recog-
ized the same linear epitopes. Lastly, the monoclonal antibodies
ereused to study if these antibodies recognizednativeMAPHsp70
rotein in lesional tissue in naturally infected animals and if they
nteract with intact bacteria.
. Materials and methods
.1. Animals and experimental design
.1.1. Mice
Two Balb/c mice, obtained from Charles River (Someren, the
etherlands), were used for the generation of MAP Hsp70 speciﬁc
onoclonal antibodies. Animals were kept under standard hous-
ng and care conditions at the Central Animal Facilities of Utrecht
niversity (Utrecht, the Netherlands).
.1.2. Goats
Thirty female goat kids (Saanen breed dairy goats, age 14±3
ays at the start of the experiment) were used. The kids were
aised using conventional procedures and feeds, and were checked
aily for general health. They were randomly assigned to one of
he four experimental groups. Goat kids in groups 1 (n=7) and 2
n=8) (uninfected controls) were housed separately from goat kids
n groups 3 (n=7) and 4 (n=8) (MAP infected). Goat kids assigned
o groups 2 and 4 were immunized once at the start of the exper-
ment (day 0). The immunization consisted of the administration
f 200g of recombinant MAP Hsp70 in 1mL phosphate buffered
aline (PBS) containing10mg/mLdimethyl dioctadecyl ammonium
romide (DDA) adjuvant (Sigma Aldrich, USA) in the ﬁnal prepara-
ion, subcutaneously in the lower neck region.
Goat kids assigned to groups 3 and 4were infected orally with 3
ral doses, at days 0, 2 and 4, of 2×109 cfu of MAP strain G195,
riginally isolated from a goat with clinical signs of paratuber-
ulosis, grown on Middlebrook 7H10 supplemented with OADC
nd Mycobactin J (a generous gift from D. Bakker, CVI, Lelystad,
he Netherlands). The cfu of the infection dose was determined by
olony counts of serial dilutions on 7H10 agar plates.
Blood samples were taken from the vena jugularis on a weekly
asis for a period of 3 months. Serum was stored at −20 ◦C, until
urther use. Goats were euthanized at the end of the experiment
nd tissue samples from ileum, jejunum, the ileocecal and a jejunal
esenteric lymph node were analyzed using MAP speciﬁc IS900
CR [16], bacterial culture on mycobactin J supplemented HEY
edium (BD Biosciences, Belgium) and histopathology.
.1.3. Cattle
Sera from cattle subjected to a Hsp70 vaccination – challengexperiment, published previously [9], were used to characterize
AP Hsp70 speciﬁc antibody responses. In short, 4 groups of 10
emale calves aged 29±9 days, randomly assigned to one of 4
xperimental groups, were used in that study. Treatment of the
roups was identical to the goat kids described in Section 2.1.3.9 (2011) 1364–1373 1365
Serum samples were taken every 2 weeks for the ﬁrst 12 months
of the experiment and monthly for the remainder 12 months.
2.2. Ethics
Animal experiments were approved by the Ethical committee
of Utrecht University, and performed according to its regulations.
2.3. Antigens
The following antigens were used for vaccination and determi-
nation of speciﬁcity of monoclonal antibodies (mAb): recombinant
MAP Hsp 65kD (rMAP Hsp60) and Hsp 70kD (rMAP Hsp70). These
antigens were produced as described earlier [6,17].
A recombinant C-terminal deletionmutant protein of theHsp70
molecule was constructed, comprising the receptor binding part. It
consisted of N-terminal amino acids 1–359 of wildtype Hsp70, had
a molecular weight of approximately 45kD and was designated
RBS70. RBS70 was constructed by restriction endonuclease diges-
tion of the original recombinant MAP Hsp70 pTrcHis expression
vector with AﬂII (NE Biolabs, USA) and HindIII (Gibco-Invitrogen,
the Netherlands) using 5 units of each enzyme per g DNA. The
digested fragment was separated from the vector DNA by agarose
gel (1%) electroforesis and isolated from the gel using a QIAEXII kit
(Promega, the Netherlands). The vector DNA was blunted by using
T4 DNA polymerase (Fermentas, Germany) subsequently puriﬁed
using a DNA cleaning kit (Zymo Research, USA), religated using T4
DNA ligase (Quick Ligation kit, NE Biolabs, USA) and puriﬁed using
the DNA cleaning kit. Finally, chemically competent Top10 bacte-
ria (Invitrogen, the Netherlands) were transformedwith the vector
DNA using a heat shock protocol provided by the manufacturer.
Transformed bacteria were selected and protein expression and
puriﬁcation was performed similar to the procedure described for
recombinant MAP Hsp70 [6].
In addition, the following antigens were used: recombinant
M. tuberculosis Hsp70 (MTb), recombinant Escherichia coli (E. coli)
Hsp70 and bovine Hsc70 puriﬁed frombovine brain (generous gifts
from Stressgen, Canada). Puriﬁed protein derivatives (PPDs) were
produced at CVI (Lelystad, theNetherlands) as previously described
[18], fromMAP strain3+5/C (PPDP),M.bovis (MB) strainAN5(PPDB),
and M. avium ssp. avium (MAA) strain D4 (PPDA). MAP strain 316F
was grown at the CVI (generous gifts from D. Bakker).
To deﬁne peptides for the screening of monoclonal antibodies
and sera from cattle and goats the following HSP70 Genbank-
derived sequenceswere used: Q00488 (MAPHsp70); A0QLZ6 (MAA
Hsp70); P0A5C0 (MBHsp70); P0A5B9 (MTbHsp70); P04475 (E. coli
Hsp70); NP776975 (Bos taurus Hsp70-1A).
A ﬁrst set of 124 synthetic 14-mer peptides, with an aminoter-
minal cysteine, a 5 amino acids (aa) shift and an overlap of 9
aa, covering the MAP Hsp70 molecule, was synthesized using
the simultaneous multiple peptide synthesis (SMPS) technique
described previously [19]. To enable di-sulphate binding of pep-
tides to the solid phase ELISA plate, an amino-terminal cysteine
residue was coupled to each peptide during synthesis. For primary
screeningpeptideswerepooled in11groupsof sequential peptides.
Positive pools were retested for the single peptide speciﬁcation.
To enable coupling of peptides to streptavidin coated beads for
the Luminex system (see below) a separate set of 14-mer MAP
Hsp70 peptides, selected based on the ﬁrst screening with the
14-mer peptides, was synthesized using SMPS and modiﬁed using
amino-terminal biotinylation.
A third set of 15-mer peptides consisting of mycobacterial,
Bos taurus and E. coli homologues to identiﬁed MAP Hsp70 lin-
ear epitopes was also synthesized using SMPS and modiﬁed using
amino-terminal biotinylation.
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Fig. 1. Characterization of rMAP Hsp70 speciﬁc hybridoma’s. Panel A: reactivity of hybridoma supernatants to rMAP Hsp70 protein, a recombinant control protein (rMAP
Hsp60 protein), and Johnin (PPDP) and avian tuberculin (PPDA). Panel B: reactivity of hybridoma supernatants to several Hsp70 proteins, recombinant mycobacterial Hsp70
from MAP and M. tuberculosis (MTb), recombinant Hsp70 from E. coli and puriﬁed bovine Hsc70. Top rows of representative table indicate the clone name (KoKo.B01–B08).
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shows the binding of antibodies (KoKo.Bo1–B08) to the recombinant MAP Hsp70
containing the N-terminal amino acids 1–359 of wildtype Hsp70). Results are pres
.4. Generation and screening of monoclonal antibodies
The generation of monoclonal antibodies has been described
reviously [20]. Brieﬂy, 100g of recombinant MAP Hsp70 pro-
ein in 80L PBS was mixed with 100L Specol [21] (Prionics, the
etherlands) to obtain a water in oil emulsion used for i.p. immu-
ization of Balb/c mice. This immunization was repeated 3 weeks
ater. Another 3 weeks later, four days prior to hybridoma produc-
ion the mice were boosted i.v. with 50g of the antigen in 50L
BS. After 4 days spleen cellswere fusedwithmousemyeloma cells
Sp2/0) using polyethyleneglycol (PEG, Merck, Germany). Antigen
peciﬁc antibody producing hybridoma’s were selected by ELISA
22] and subcloned in limiting dilution. The isotype of the mon-
clonal antibodies was determined using the Mouse Hybridoma
ubtyping Kit (Roche, the Netherlands)..5. ELISA
In general, 96 well EIA plates (Corning Costar Corp., USA) were
oatedwith 100L of antigen diluted in sodiumbicarbonate buffer
pH 9.6), for 60min at 37 ◦C. All subsequent incubations were05nm of background control samples +3× SD) in two separate experiments. Panel
in (black bars) and the recombinant deletion mutant protein RBS70 (hatched bars)
as the average OD405+SD of 3 independent experiments.
performed for 30min at 37 ◦C, and after each incubation step
plates were washed 3 times with PBS containing 0.05% Tween
20. Wells were blocked with 200L blocking solution (Roche, the
Netherlands). All antibody fractions were diluted in blocking solu-
tion and peroxidase labelled to appropriate antibodies was used as
enzyme.
Finally, plates were washed extensively, and 100L ABTS
(2,2′-azinobis (3 ethyl) benzthiazolinsulfonic acid (Roche, the
Netherlands) substrate buffer was added to each well. The optical
density (OD)wasmeasuredafter10minat405nmonaspectropho-
tometric Elisa reader (Bio-Rad laboratories, USA). Absorbance
values were subsequently analyzed.
2.5.1. Protein ELISA’s
TheMAPHsp70 protein, bovine Hsc70 protein, PPDP, PPDA, and
PPDB ELISA tomeasure antibody responses in cattle sera were per-
formed according to methods described previously [6] with minor
modiﬁcations to detect murine and caprine antibodies as follows.
Hybridoma supernatants or sera of immunized/infected goatswere
used in a predetermined optimal dilution or were serially diluted
in blocking buffer as indicated. Secondary antibodies used were
W. Santema et al. / Vaccine 29 (2011) 1364–1373 1367
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ith synthetic MAP Hsp70 peptides. Antibody reactivity was tested on individual pe
aa. (Panel A) KoKo.B01 (panel B) KoKo.B02, and (panel C) KoKo.B03 test results ar
olyclonal goat anti-mouse peroxidase (PO) conjugated antibod-
es (Sigma Aldrich, USA) to detect murine monoclonal antibodies,
nd rabbit anti-goat IgG-PO (Sigma Aldrich, USA) to detect caprine
ntibodies.
.5.2. The mycobacterial whole cell ELISA
The mycobacterial whole cell ELISA was a modiﬁcation to
he protein ELISA. In brief, 96-well plates (Corning Costar Corp.,
SA) were coated with 100L of washed bacteria (both MAP and
AA; 1×108 cfu/mL), diluted in sodium bicarbonate buffer pH 9.6
or 60min at room temperature, while shaking at 300 rpm on a
lectronicMTS shaker (IKAWerke, Germany). All subsequent incu-
ations were performed for 30min shaking at room temperature.
fter each incubation step, plates were washed three times with
BS containing 0.01% Tween 20. The secondary antibody was goat
nti-Mouse (GAM)-PO (Roche, the Netherlands) 1:2000..5.3. Peptide ELISA
Peptide ELISA was used for the initial epitope mapping of the
onoclonal antibodies generated against MAP Hsp70. The peptide
LISAusing cys-linkedpeptides has beendescribedpreviously [23].
hedifferent cys-linkedpeptideswerediluted in0.1MTris–HCl, pHtibodies showing reactivity with recombinantMAPHsp70were tested for reactivity
s of a positive 14-mer peptide pool, with a 5 amino acid (aa) shift and an overlap of
ented as the average optical density at 405nm (OD405) + SD.
8.0 at a concentration of 15g/mL, and 100L was added at each
well.
2.6. Flowcytometric analysis of monoclonal antibodies binding to
mycobacteria
To study whether monoclonal antibodies bind to intact bacte-
ria, indicative of the presence of MAP Hsp70 in the bacterial cell
wall, suspensions of MAA strain D4 and MAP strain 316F (gener-
ous gifts from D. Bakker, CVI) were prepared from log phase liquid
cultures. Suspensions of MAA and MAP (both 1010 bacteria/mL
in PBS) were diluted 1:100, washed three times by centrifuga-
tion (1min at 14,000RPM in an Eppendorf centrifuge (Eppendorf,
Germany)) and resuspended in PBS. These suspensions were
diluted 1:100 in PBS supplemented with 1% BSA and 0.01% sodium
azide (both from Sigma Aldrich, USA) and divided in volumes of
100L. The Hsp70 speciﬁc monoclonal antibodies were added in
a concentration of 5g/mL. After incubation for 25min at room
temperature (RT) and three washes with PBS supplemented with
1% BSA and 0.01% sodium azide (FACS buffer), FITC-labelled Goat
anti-mouse antibodies (Becton-Dickinson, USA) were added and
incubated for 25min at RT. After three more washes, 10,000 bac-
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Fig. 3. Speciﬁcity of KoKo.B02 and KoKo.B03mAb’s binding linear epitopes ofMAPHsp70. Speciﬁcity of (Panel A) KoKo.B02 (IgG2b)mAb and (Panel B) KoKo.B03 (IgG2a)mAb
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ontrols.
erial cells were used for analysis by FACScan (Becton-Dickinson,
SA).
.7. Luminex multiplex immunoassay
Multiplex peptide speciﬁc antibody measurements were per-
ormed using biotinylated peptides linked to avidin coated
uorescent microspheres (LumAv, Luminex, USA) on a Luminex
00 platform according to instructions provided by the manufac-
urer (Luminex). A total of 2.5×105 beads (100L) per uniquely
abelled beadset were washed twice with PBS, and subsequently
ncubated with 10mol biotinylated peptide for 10min at 20 ◦C.
fter two washes with PBS, the beads were resuspended in their
riginal volume (100L) using PBS supplemented with 1% bovine
erum albumine (Sigma Aldrich, USA) and 0.01% sodium azide,
nd stored in the dark at 4 ◦C until further use. For multiplex
nalysis 20L of resuspended coated beads of each of up to 20
nique beadsets were pooled in an eppendorf container. To the
nal volume of beads, the same volume of PBS was added, and
ixed.
In a round bottom 96 well microtiter plate, 10L of the mixed
eads was added per well. Subsequently, 100L of goat or calf
erum per well was added. This mixture was incubated for 30min
t 4 ◦C and subsequently washed once with PBS supplemented
ith 1% bovine serum albumine (Sigma Aldrich, USA) and 0.01%
odium azide. Next, bead-bound antibodies were labelled with
0L 1:5000 diluted protein-A-RPE (Prozyme, USA). This mixtureeads (LumAv), containing relevant MAP Hsp70 peptides as well as (myco)bacterial
d as the mean ﬂuorescent intensity (MFI) + SD and compared with matched isotype
was incubated for 30min at 4 ◦C at which point 100L PBS supple-
mented with 1% bovine serum albumine (Sigma Aldrich, USA) and
0.01% sodium azide was added. The 96 well plate was placed in the
Luminex 100 analyzer and per sample the amount of PE derived
ﬂuorescence was measured for each of the 20 unique beadsets by
acquisition of data of 100 beads per set and expressed as mean ﬂu-
orescence intensity (MFI) as a measure for antibody bound to the
peptide coupled to the designated beads.
2.8. Immunohistochemistry
Selected recombinant Hsp70 speciﬁc monoclonal antibodies
recognizing linear epitopeswereused in immunohistology to study
whether these epitopes were detectable in wildtype MAP, present
in infected lesional tissue. Tissues samples from archived formalin
ﬁxed, parafﬁn embedded tissues were used from cattle diagnosed
with paratuberculosis and uninfected control animals. Microbio-
logical and immunological characterization of these cattle samples
has been published previously [7].
Tissue specimens were processed by routine methods for
microscopic examination using a Haematoxylin and Eosin (H&E)
and Ziehl–Neelsen (ZN) stains. For immunohistology tissue sec-
tions were dewaxed in xylene and rehydrated through graded
alcohols for 2min each step till distilled water. They were
then pre-treated with Citrate buffer pH 6.0 in microwave
700W for 10min. Endogenous peroxidase activity was sup-
pressed by 1% H2O2 in methanol for 30min. This was followed
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Fig. 4. rMAP Hsp70 vaccinated calves and goats recognize linear B cell epitopes of MAP Hsp70. Panel A shows rMAP Hsp70-speciﬁc serum antibody responses in vaccinated
goats and controls. Goats were immunized with 200g of rMAP Hsp70 in 1mL phosphate buffered saline (PBS) containing 10mg/mL DDA adjuvant (group 2 () n=7 and
group 4 () n=8) at time point week 1. Animal in group 3 (X) and group 4 () were experimentally infected with MAP during the ﬁrst week with 3 doses of MAP one day
apart. Animals in group 1 () n=7were neither immunized nor infected. Serawere prediluted 1:20, results are expressed as the average OD405 of animals in the group+SEM.
Panel B (goats) and panel C (calves) shows a multiplex Luminex analysis of serum antibody responses to a set of 14-mer biotinylated MAP Hsp70 peptides. Animals were
immunizedwith 200g of recombinantMAPHsp70 in 1mL phosphate buffered saline (PBS) containing 10mg/mL dimethyl dioctadecyl ammonium bromide (DDA) adjuvant
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roup+SEM. Bars related to responses to a peptide that do not share letters are sign
y treatment with 10% normal horse serum (NHS) 1:10 in
BS for 15min for removal of non-speciﬁc reactivity and
y incubation with primary antibody (4 ◦C overnight). The
econdary antibody (biotin labelled horse anti-mouse 1:125,
ako, Denmark) was applied for 30min at room tempera-
ure. The two solutions A and B of the ABC kit were diluted
5 times in PBS, mixed and the ABC reagent was stored
or 30min until further use. Then the slides were incubated
or 30min with ABC-complex at room temperature. Conju-
ate binding was detected by adding the substrate chromogen
3.3-diaminobenzidine, DAB) and color was allowed to develop
or 10min. Finally, tissue sections were washed with distilled
ater, counter-stainedwith haematoxylin, rinsed, dehydrated and
ounted..9. Statistical analysis
Data were analyzed using SPSS v15 software. Student t-test or
NOVAwere used as indicated. Level of statistical signiﬁcance was
et at p<0.05.(dark grey bars) and group 4 were experimentally infected with MAP. Animals in
2, results are expressed as the mean ﬂuorescence intensity (MFI) of animals in the
tly different at p<0.05 according to ANOVA.
3. Results
3.1. Characterization of rMAP Hsp70 speciﬁc monoclonal
antibodies
Eight hybridoma supernatants reacted with rMAP Hsp70. None
of these 8 supernatants reacted with rMAP Hsp60 or PPD-A con-
trol antigens, 3 supernatants recognized their epitope in PPDP
(KoKo.B03, KoKo.B05, KoKo.B06) (Fig. 1A).
Furthermore, these 8 culture supernatants were screened for
reactivity with rHsp70 from MTb, E. coli and puriﬁed bovine
Hsc70 to identify cross-reactivity. Four supernatants reacted only
with MAP Hsp70 (KoKo.B01, KoKo.B02, KoKo.B05, KoKo.B06),
three supernatants also recognized recombinant Hsp70 from
MTb (KoKo.B03, KoKo.B04, KoKo.B08), 3 supernatants recognized
bovineHsc70 (KoKo.B04, KoKo.B07, KoKo.B08) and only one super-
natant recognized recombinant Hsp70 from E. coli (KoKo.B03)
(Fig. 1B).
Comparison of binding of the 8 MAP Hsp70 speciﬁc monoclonal
antibodies in ELISA to the recombinant deletion mutant protein
RBS70 (containing the N-terminal amino acids 1–359 of wild type
1 ccine 29 (2011) 1364–1373
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Fig. 5. MAP Hsp70 linear B cell epitopes are recognized in the cell wall of MAP.
Panel A, whole mycobacterial cell ELISA testing binding of antibody KoKo.Bo3 to
M. avium spp. paratuberculosis (MAP), M. avium spp. avium (MAA), and M. bovis
(MB) and panel B, testing of antibody KoKo.Bo1 (MB not determined). Results are
presented as the average OD405+SD, p-values reﬂect comparison ofMAP andMAA,
p<0.001. Panel C shows ﬂow cytometric analysis of MAP Hsp70 speciﬁc antibodies
KoKo.B01 and B03 after binding to live bacteria. White bars are results obtained
using MAA strain D4, solid black bars are results using MAP strain 316F. Results are
expressed as the percentage of propidium iodine negative bacteria which display370 W. Santema et al. / Va
APHsp70) indicated that KoKo.B01, KoKo.B02 and KoKo.B06 rec-
gnize an epitope at the C-terminus of Hsp70, which is not present
n RBS70. The other ﬁve antibodies recognized epitopes in the N-
erminal RBS70 mutant molecule (Fig. 1C).
.2. MAP HSP70 contains multiple linear B cell epitopes
All 8 antibodies reacting with recombinant MAP Hsp70 were
ested for recognition of synthetic MAP Hsp70 peptides to iden-
ify linear epitopes. In a primary screening, three antibodies
KoKo.B01, KoKo.B02 and KoKo.B03) displayed reactivity to spe-
iﬁc pools of MAP Hsp70 peptides (data not shown). The other
ve monoclonal antibodies did not recognize linear peptide epi-
opes. Subsequent, ﬁne mapping of the epitopes using the single
eptides of the pools in a solid phase ELISA conﬁrmed that
oKo.B01, KoKo.B02, KoKo.B03 recognized linear epitopes in MAP
sp70. The antibodies KoKo.B01 (IgG1 isotype) and KoKo.B02
IgG2b isotype) recognized the aminoacid sequence P595–603
PDGAAAGGG) (Fig. 2A andB), located in theC-terminal part ofMAP
sp70. The third antibody, KoKo.B03 (IgG2a isotype), recognized a
onservedepitope in theN-terminusof theMAPHsp70proteinwith
he apparent core region sequence P111–124 (ITDAVITVPAYFND)
Fig. 2C).
The speciﬁcity of the monoclonal antibodies KoKo.B01–03 in
elation tohomologousHsp70proteinswas testedbyLuminexmul-
iplex immunoassay. The data indicated that KoKo.B01 (not shown)
nd KoKo.B02 recognize an epitope which is present and identical
n Hsp70 from MAP and MAA, but absent in Hsp70 from MB, MTb,
nd E. coli and bovine Hsc70 (Fig. 3A). Finally, the data regarding
oKo.B03 indicate that conserved mycobacterial homologues (MB,
Tb) are equally well recognized, while recognition of the E. coli
omologue is at approximately 50% of that of the MAP epitope,
hile recognition of the bovine homologue is near background
evels (Fig. 3B).
.3. Recognition of linear B cell epitopes of MAP Hsp70 by cattle
nd goats sera
In cattle, Hsp70 speciﬁc antibody responses were detected 3
eeks post vaccination [9] (data not shown). In goats, Hsp70 spe-
iﬁc antibody responses were detected 4 weeks post vaccination,
emained stable between 4 and 12 weeks post vaccination and
ere not inﬂuenced by exposure to MAP (Fig. 4A). The MAP Hsp70
ntibody responses in unvaccinated goats remained at background
evels during 12 weeks irrespective of exposure to MAP. Similar
inetics were observed using the ELISA with the RBS70 molecule
data not shown). Sera obtained at 3 (cattle) and 4 (goats) weeks
ost vaccination were analyzed for the presence of Hsp70 speciﬁc
ntibodies directed at the protein regions identiﬁed by the mouse
onoclonal antibodies by incubation of the sera with 7 different
sp70 peptides. Recognition patterns of P111–124, and 6 peptides
omprising the less conserved C-terminus of Hsp70 are shown
n Fig. 4B. These indicated that in vaccinated goats the dominant
esponses are directed against the peptides P111–124, P605–618,
nd P610–623.
Vaccination with simultaneous exposure to MAP does not
lter responses to P111–124, and P605–618. Lower responses are
etected for P610–623, in MAP exposed groups as compared to
hose after vaccination alone. Similar differences were observed at
ater time points (data not shown).
In calves (Fig. 4C) the dominant responses in vaccinates are
irected against the peptides P111–124, P590–603, P600–613, and
610–623. Simultaneous exposure toMAP does not alter responses
o P111–124; lower responses are detected to P590–603; and
600–613 is recognized preferentially by vaccinated and MAP
xposed calves. Finally, P610–623 is recognized by Hsp70 vacci-positive staining with the FITC conjugated Goat-anti-Mouse second step antibody.
Isotype control mAb for KoKo.Bo3 (IgG2a) and KoKo.B01 (IgG1) were included to
investigate background staining. For each condition staining of 10,000 live bacteria
was analyzed.
nated calves only. Similar datawere obtainedwith sera from calves
at later time points post vaccination (data not shown).
Vaccinated goats and calves recognized the same epitopes as
KoKo.B01–03.
3.4. MAP Hsp70 linear B cell epitopes are recognized in the cell
wall of MAP
Based on comparable recognition of the identiﬁed linear epi-
topes in Map Hsp70 by antibodies from cattle, goats and mice,
and to circumvent problems associated with polyclonal sera, the
mouse monoclonal antibodies (KoKo.B01–03) were used to study
interactions withMap in whole cell ELISA. Both described epitopes
(P111–124 and P595–603) were recognized in the cell wall ofMap.
Despite high sequence similarities of MAP and MAA Hsp70 protein
(99.8% similarity, the only difference being Q198H), reactions with
intact MAA were signiﬁcantly lower in ELISA (p<0.001) compared
to reactions with intact MAP (Fig. 5A and B). A low reaction was
observed with MB.
Similar data were obtained for KoKo.B01 and KoKo.B03 using
a ﬂowcytometric approach to address the binding of antibodies to
intact livingmycobacteria, an example ofwhich is shown in Fig. 5C.
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Fig. 6. Staining of sequential lesional tissue sections from the ileum of a cow diagnosed with paratuberculosis by MAP Hsp70 speciﬁc monoclonal antibody KoKo.Bo2.
Sequential sections of this paratuberculosis diagnosed cow, showing clinical signs, were processed using routine HE staining (panels A and B), Ziehl–Neelsen staining for acid
fast bacteria (panels C and D), immunohistochemical staining with an isotype control antibody (panels E and F) and stained for MAP Hsp70 with KoKo.B02 (panels G and H).
The left panels (A, C, E and G) are 200× magniﬁcations and the right panels (B, D, F and H) are 400× magniﬁcations of a section of the left panels.
1 ccine
3
p
f
o
t
p
b
i
e
c
a
s
4
b
M
T
p
s
w
H
t
a
t
r
c
a
b
a
c
c
m
H
i
[
m
c
i
K
p
i
t
n
N
t
p
w
c
p
r
H
t
t
i
r
B
M
t
n372 W. Santema et al. / Va
.5. MAP Hsp70 is present in lesional tissue from
aratuberculosis infected animals
The KoKo.B02 and KoKo.B03 antibodies recognizing two dif-
erent linear epitopes of MAP Hsp70, also recognized by sera
f immunised goats and cattle, were tested for recognition of
hese epitopes in immunohistochemical analysis of formalin ﬁxed,
arafﬁn embedded bovine tissue. Both antibodies recognized the
acteria in situ in tissue sections (N=3, independent animals),
ndicating that the epitope, and therefore the Hsp70 protein, is
xpressed by MAP in intestinal lesions. Fig. 6 shows immunohisto-
hemical staining of MAP infected intestinal tissue with KoKo.B02;
n isotype control antibody was used at equal concentrations and
howed no staining.
. Discussion
This study indicates that the Hsp70 protein is accessible to anti-
odies both on intact MAP bacteria in suspension as well as on
AP incorporated in lesional tissue of cows infected with MAP.
he presence of the Hsp70 protein in the cell wall appears more
ronounced in MAP as compared to MAA, despite high sequence
imilarities of MAP and MAA Hsp70 protein. In a previous study
e showed that vaccination of cattle with recombinant MAP
sp70 signiﬁcantly reduced bacterial shedding [9]. This reduc-
ion coincided unexpectedly with a clear Hsp70 antibody response
nd a limited cell mediated response. This suggests that induc-
ion of Hsp70 antibodies could contribute to effective immune
esponses against Map in vivo. Similar to the smaller 16kD -
rystallin heat shock protein with respect to MTb [15], Hsp70
ppears to be present in the intact cell wall of MAP, as evidenced
y a recent study identifying cell wall proteins using a proteomics
pproach [24]. Furthermore it has been shown that local appli-
ation of speciﬁc monoclonal antibodies to the 16kD -crystallin
onfers protection to early stage tuberculous infection in a murine
odel of tuberculosis [15]. Thus, likewise, antibodies speciﬁc for
sp70 may contribute to protective immunity in mycobacterial
nfections, which other studies have also indicated (reviewed in
14]).
We characterized MAP Hsp70 B cell epitopes recognized by
urine monoclonal antibodies as well as sera from Hsp70 vac-
inated goat and cattle. Our synthetic peptide approach resulted
n deﬁnition of two linear epitopes. One of them (recognized by
oKo.B03) is located in the conserved N-terminus of the native
rotein, while the other (recognized by KoKo.B01 and KoKo.B02)
s located in the less evolutionary conserved C-terminal region of
he protein. Five more monoclonal antibodies most likely recog-
ized conformational epitopes, of which four are located in the
-terminus of MAP Hsp70. Although we were not able to ﬁne-map
hese epitopes, this ﬁnding shows that Hsp70 contains multi-
le targets for antibody interactions. Immunization of mice with
hole-cell extracts of MAP also led to the generation of mono-
lonal antibodies speciﬁc for Hsp70 (MAP3840), indicating that this
rotein is immunogenic and abundantly present in MAP [25].
The intact protein, as well as the dominant linear epitopes were
ecognized by antibodies of cattle vaccinated with recombinant
sp70 protein. Whether or not these calves were experimen-
ally infected with MAP did not alter the antibody response to
hese epitopes. Similar results were obtained with goat kids. Both
n goats and calves, the experimental exposure to MAP concur-
ent with vaccination did not substantially inﬂuence the major
cell responses to vaccination with Hsp70. In the C-terminus of
AP Hsp70 other linear epitopes were also recognized, indicating
hat in vaccinated calves and goats multiple targets are recog-
ized.29 (2011) 1364–1373
For diagnostic purposes the combined use of antibodies spe-
ciﬁc for the C-terminal and N-terminal epitopes of Hsp70 offers
possibilities as an alternative to Ziehl–Neelsen staining, increasing
speciﬁcity for detection of mycobacteria in diagnostic specimen.
The known speciﬁcity of the monoclonal antibodies KoKo.B01–03
allows differentiation between MAP/MAA Hsp70 and pathogenic
MTb complex species and M. leprae (MLE) Hsp70. In addition, out-
side the genus mycobacterium, these mAb can distinguish the
presence of MAP/MAA Hsp70 from Hsp70 of other prokaryotic ori-
gin,without cross-reactionwith eukaryotic (host) 70kDheat shock
proteins.
This and previous studies show that in naturally acquired
paratuberculosis or experimental infection very little Hsp70 spe-
ciﬁc antibody is formed, while the Hsp70 protein does induce a
cell mediated response [5,6,9]. Pathogen derived Hsp70 may be
present in debris of dead mycobacteria and apoptotic bodies from
infected host cells, and thus taken up and processed by antigen
presenting cells. In the context of local mycobacterial infection,
especially in early stages of paratuberculosis, adaptive immune
responses have a Th1 signature and responses to various anti-
gens may be skewed in this direction under these conditions
[26].
In contrast however, following vaccination with MAP Hsp70
formulated with DDA adjuvant a dominant antibody response is
mounted against the protein. We have recently shown that epi-
topes fromMAPHsp70activatebovineThelper cells, including IFN
producing CD4+ Th1 T cells in a MHC class II restricted manner in
MAPHsp70 vaccinated cattle [27]. However following a short mea-
surable induction of cell mediated immunity to Hsp70, we have
very little evidence of a substantial prolonged period of activa-
tion of Hsp70 speciﬁc cell mediated immunity after Hsp70/DDA
vaccination [9,10,28].
In general, the (local) skewing of immune responses follow-
ing infection is the result of host pathogen interaction. Since
MAP infects and manipulates antigen presenting cells the adaptive
response induced by infection may therefore not give rise to the
optimal protective response [29,30]. Especially in paratuberculosis
the Th1 directed responses in early stages of infection are easily
detected [31]; however most animals do not recover from infec-
tion but become chronically infected, pointing towards insufﬁcient
protective immunity. An early adequate antibody response to sur-
face exposed antigens, not readily induced by natural contact with
intact mycobacteria, may therefore be an additional feature of pro-
tective immunity in addition to cell mediated responses as a result
of Hsp70/DDA subunit vaccination.
In conclusion, this study demonstrates that at least two dom-
inant linear B cell epitopes are present in the Hsp70 molecule.
These epitopes are present in the bacterial cell wall of MAP and
accessible to antibodies. Itmay be argued that vaccination-induced
antibodies, apparently not produced during MAP infection as such,
indeed bind intact bacteria and possibly alter their cellular fate fol-
lowing uptake by macrophages and other antigen presenting cells.
Next to IFN producing Th1 cells, these Hsp70-speciﬁc antibodies
may play a role in the protective effect shown after Hsp70/DDA
subunit vaccination against bovine paratuberculosis [9].
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